Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/365—Lactones
  • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/365—Lactones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients

Definitions

• Lipid storage disorders are a group of inherited metabolic disorders in which harmful amounts of lipids accumulate in some of the body's cells and tissues. People with these disorders generally either do not produce enough of one of the enzymes needed to metabolize lipids or they produce enzymes that do not work properly. Over time, this excessive storage of fats can cause permanent cellular and tissue damage.
• lipid storage disorders lack adequate therapeutics for treatment. These disorders include, for example, Niemann-Pick disease types A, B and C, Gaucher disease Type II, Fabry disease (note that an enzyme replacement is available), gangliosidoses including Tay-Sachs disease, Sandhoff disease, Krabbe disease, Metachromatic leukodystrophy, and cholesteryl ester storage disease (Wolman's disease).
• Niemann-Pick disease types A, B and C Gaucher disease Type II
• Fabry disease note that an enzyme replacement is available
• gangliosidoses including Tay-Sachs disease, Sandhoff disease, Krabbe disease, Metachromatic leukodystrophy, and cholesteryl ester storage disease (Wolman's disease).
• Niemann-Pick disease is an inherited autosomal recessive lipid storage disorder characterized by excessive accumulation of sphingomyelin in the lysosomes of cells such as macrophages and neurons, which impairs normal cellular function.
• Niemann-Pick Type A results from a deficiency of acid sphingomyelinase and is a rapidly progressive neurodegenerative disease. It typically results in death within two to three years of age.
• Niemann-Pick Type B is a milder form that results in the enlargement of the liver and spleen, and respiratory distress with death generally ensuing by early adulthood.
• ASM deficiency ASM deficiency
• Other types of Niemann-Pick disease e.g., Type C, do not involve mutations in the ASM gene and are not directly attributable to the function of ASM.
• the nature of the biochemical and molecular defects that underlie the remarkable clinical heterogeneity of the A and B subtypes remains unknown.
• patients with both subtypes have residual ASM activity (about 1 to 10% of normal), biochemical analysis cannot reliably distinguish the two phenotypes.
• Type B NPD is highly variable, and it is not presently possible to correlate disease severity with the level of residual ASM activity.
• Niemann-Pick Type C is results from mutations in NPC1 and NPC2 genes.
• the protein product of the major mutated gene NPC1 is not an enzyme but appears to function as a transporter in the endosomal-lysosomal system, which moves large water-insoluble molecules through the cell.
• the protein coded by the NPC2 gene has been shown to be a small cholesterol-binding protein that resides in the lysosome lumen. The disruption of this transport system results in the accumulation of cholesterol and glyco lipids in lysosomes.
• Niemann Pick disease is a disorder for which there remains an overwhelming need for therapeutics for treatment.
• PLC protein kinase C
• Vimentin is involved in a variety of cellular processes, including vesicular membrane transport [6,7], signal transduction [8,9] and cell motility [10]. Similar to NPCl cells, cells lacking vimentin are unable to transport LDL-derived cholesterol from their lysosomes to the endoplasmic reticulum for esterification [11]. The decreased vimentin phosphorylation in NPC 1 cells reduces the pool of soluble vimentin, likely disrupting the vimentin cycle, which is necessary for transport to take place [12,13]. Vimentin has been shown to be phosphorylated by several proteins, including the PKCs [14] and in particular the a [15], ⁇ [10] and ⁇ [16,17] isoforms.
• the present disclosure provides methods for treating human subjects suffering from lipid storage disorders, such as Niemann-Pick disease, by administering PKC activators.
• the present disclosure provides, according to certain embodiments, methods comprising administering to a subject with a lipid storage disorder a pharmaceutically effective amount of a PKC activator.
• the present disclosure provides, according to certain embodiments, methods comprising administering to a subject with Niemann-Pick Type C disease a
• Figure 1A and IB is a Western blot showing the effects of transient PKC expression on vimentin solubilization in human NPC1 cells.
• Representative Western blot analyses of soluble and insoluble vimentin levels in human NPC1 3123 (A) and human nuUNPClo (B) cells transfected with PKC ⁇ , ⁇ , or a show that the three iso forms increase levels of soluble vimentin and Rab9 with a concurrent decrease of insoluble vimentin relative to untransfected cells (-).
• the levels of vimentin solubilized are similar to that seen in cells expressing Rab9 (Rab9).
• the blots shown are representative of at least 3 independent experiments.
• Figure 2 is a Western blot showing Rab9 release from insoluble vimentin fraction of NPC1 cell lysates.
• the insoluble vimentin fraction from NPCl cell lysates was incubated with various PKC isoforms. All isoforms tested can affect Rab9 release to some degree from the insoluble vimentin fraction, with PKCa being the most effective and PKCy being the least effective.
• the blots shown are representative of at least 3 independent experiments.
• FIG. 3 is a graph showing the effects of PKCs and fatty acids on cholesterol esterification in M12 NPC1 CHO cells.
• M12 cells were treated with 50 ⁇ g/ml fatty acids for 2 days and then transfected with the indicated PKC isoforms. Following transfection, cholesterol transport was assessed by esterification assay. Both free fatty acids and PKCs alleviate the cholesterol transport defect of NPC1 cells and their effects appear to be additive.
• Figure 4 are images showing the effects of transient PKC expression on the NPC1 phenotype.
• Ml 2 cells were transfected with PKC isoforms or Rab9 for 48 hrs and then analyzed by filipin staining for cholesterol storage.
• Cells positive for transfection stain positive for GFP left panel
• show decreased filipin staining outlined cells, right panel
• Figure 5 shows the effects of fatty acids on vimentin solubilization and the NPC 1 phenotype.
• FIG. 6 shows the effects of PKC activation on the NPCl phenotype.
• NPCl CHO cells B through F were treated with 100 ⁇ DCP-LA (C), 10 ⁇ DHA (D), or 100 ⁇ diazoxide (E) and cholesterol storage was quantified by filipin fluorescence.
• WT CHO cells are shown in (A).
• Filipin intensity was quantitated in at least 150 cells for each sample.
• the bar graph represents average values ⁇ SEM from 3 independent experiments. *, **, and *** denote statistically significant differences between treated and untreated cells with P ⁇ 0.05, P ⁇ 0.01 and PO.0001 , respectively, as determined by Student's t-test.
• FIG. 7 are images showing the effects of PKC activation on sphingo lipid transport.
• Human NPCl 3123 cells were treated with (B) 20 ⁇ DCP-LA, (C) 2 ⁇ oleic acid, (D) 2 ⁇ linoleic acid, or (F) ⁇ PMA for 48 hours before BODIPY- LacCer staining was performed.
• TGN trans- Golgi network
• FIG. 7 are images showing the effects of PKC activation on sphingo lipid transport.
• Figure 8 is a graph showing the ability of DCPLA, diazoxide and bryostatin 1 to decrease stored cholesterol levels in NPC3-SV cells at 48h.
• Figure 9 is a graph showing the ability of DCPLA, and bryostatin 1 to decrease stored cholesterol levels in NPC3-SV cells at 72h.
• Figure 10 is a graph showing the ability of DCPLA, and bryostatin 1 to decrease stored glycosphingolipid levels in NPC3-SV cells at 72h using verotoxin B (VTB) as a probe stain.
• VTB verotoxin B
• Figure 11 is a graph showing the ability of DCPLA and bryostatin 1 to decrease filipin accumulation using an NPC24-SV cell line.
• Figure 12 are photomicrographs showing the ability of DCPLA, and bryostatin 1 to release the ganglioside transport block in NPC3SV cells.
• Figure 13 is a graph showing the ability of bryostatin 1 (0.1-100 nM) to decrease cholesterol accumulation in human NPC24-SV cells.
• Figure 14 is a graph showing the ability of bryostatin 1 (0.1-100 nM) to decrease glycosphingolipid accumulation in human NPC24-SV cells.
• Figure 15 are images showing representative fields of treated cells used in the analysis shown Figures 13-14.
• Figure 16 is a graphic representation of an NPCl cell showing the itineraries of various lipids stored.
• Figure 17 is a graph showing untreated C57 NPCl mice. Weight gain is observed up to around day 70-72 of life after which a rapid weight loss is observed.
• protein kinase C activator or “PKC activator” refers to a substance that increases the rate of the reaction catalyzed by protein kinase C, upregulates the expression of PKC (e.g., upregulates the expression of PKCa, PKC ⁇ , PKC ⁇ and/or PKC ⁇ ), or otherwise facilitates the activation of PKC.
• the present disclosure provides methods comprising administering to a human subject with a lipid storage disorder a pharmaceutically effective amount of a PKC activator.
• the PKC activator may be administered as part of a composition suitable for administration to a human subject.
• the PKC activator may be any of bryostatin 1-20, a bryolog, neristatin, a polyunsaturated fatty acid, or a combinations thereof.
• Bryostatins may be used in the methods of the present disclosure.
• the bryostatins are a family of naturally occurring macrocyclic compounds originally isolated from marine bryozoa.
• bryostatin 1 and derivatives of bryostatm 1 are described in U.S Pat. No. 4,560,774 (incorporated herein by reference).
• suitable bryostatins include, bryostatin 1, bryostatin 2, bryostatin 3, bryostatin 4, bryostatin 5, bryostatin 6, bryostatin 7, bryostatin 8, bryostatin 9, bryostatin 10, bryostatin 11, bryostatin 12, bryostatin 13, bryostatin 14, bryostatin 15, bryostatin 16, bryostatin 17 bryostatin 18, bryostatin 19, and bryostatin 20.
• Analogs of bryostatins also may be used in the methods of the present disclosure.
• Bryologs are structural analogues of bryostatin. While bryostatin has two pyran rings and one 6-membered cyclic acetal, in most bryologs one of the pyrans of bryostatin is replaced with a second 6-membered acetal ring. This modification reduces the stability of bryologs, relative to bryostatin, for example, in both strong acid or base, but has little significance at physiological pH.
• Bryologs also have a lower molecular weight (ranging from about 600 to 755), as compared to bryostatin (988), a property which may facilitate transport across the blood-brain barrier.
• suitable bryologs include, but are not limited to analogs and derivatives of bryostatins such as those disclosed in U.S. Pat. Nos. 6,624,189, 7,256,286 and 8,497,385 (the disclosures of which are incorporated herein by reference).
• polyunsaturated fatty acid esters may be used in the methods of the present disclosure for treating lipid storage disorders.
• a PUFA is a fatty acid containing more than one double bond.
• omega-3 PUFAs the first double bond is found 3 carbons away from the last carbon in the chain (the omega carbon).
• omega-6 PUFAs the first double bond is found 6 carbons away from the chain and in omega-9 PUFAs the first double bond is 9 carbons from the omega carbon.
• PUFA includes both naturally-occurring and synthetic fatty acids.
• a major source for PUFAs is from marine fish and vegetable oils derived from oil seed crops.
• Examples of PUFA's suitable for use in the methods of the present disclosure include, but are not limited to, esters of 8-[2-(2-pentyl- cyclopropylmethyl)cyclopropyl]-octanoic acid (DCPLA), as well as those described in United States patent 8,163,800 and in PCT publication WO 2010014585 Al .
• DCPLA 2-(2-pentyl- cyclopropylmethyl)cyclopropyl]-octanoic acid
• PKC activators include potassium channel activators such as, for example, diazoxide.
• neristatins such as neristatin 1
• neristatin 1 may be used in the methods of the present disclosure for treating lipid storage disorders.
• PKC activators include, but are not limited to, phorbol- 12- myristate- 13 -acetate (PMA), okadaic acid, l ,25-dihydroxyvitamin D3, 12- deoxyphorbol- 13 -acetate (prostratin), 1 ,2-dioctanoyl-sn-glycerol (DOG), l-oleoyl-2- acetyl-sn-glycerol (OAG), (2S,5S)-(E,E)-8-(5-(4-(trifiuoromethyl)phenyl)-2,4- pentadienoylamino)benzolactam (a-amyloid precursor protein modulator), cis-9- octadecenoic acid (oleic acid), ingenol 3-angelate, resiniferatoxin, L-a-Phosphatidyl-D- myo-inositol-4,5-bisphosphat
• a pharmaceutically effective amount is an amount of a pharmaceutical compound or composition having a therapeutically relevant effect on a lipid storage disorder.
• a therapeutically relevant effect relates to some improvement in a biomechanical process (e.g., gait, use of limbs, and the like) or a change in the cellular, physiological or biochemical parameters associated with any of the causes of a particular lipid transport disorder (e.g., vimentin solubility, cholesterol esterification, cholesterol accumulation and transport, glycosphingolipid accumulation and transport).
• a pharmaceutically effective amount for bryostatins and bryologs may be from about 0.0000001 to about 500 mg per kg host body weight per day, which can be administered in single or multiple doses.
• the dosage level may be: from about 0.0000001 mg/kg to about 250 mg/kg per day; from about 0.0000005 mg/kg to about 100 mg/kg per day; from at least about 0.0000001 mg/kg to about 250 mg/kg per day; from at least about 0.00000005 mg/kg to about 100 mg/kg per day; from at least about 0.000001 mg/kg to about 50 mg/kg per day; or from about 0.00001 mg/kg to about 5.0 mg/kg per dose.
• the dosage may be about 0.00000001 mg/kg to about 0.00005 mg/kg; 0.00005 mg/kg to about 0.05 mg/kg; ; about 0.0005 mg/kg to about 5.0 mg/kg per day; about 0.0001 mg/kg to about 0.5 mg/kg per dose; or 0.001 to 0.25 mg/kg per dose.
• a pharmaceutically effective amount of a PKC activator may be an amount sufficient to solubilize vimentin and/or release trapped Rab9.
• the dosing is from about 1 ⁇ g/kg (3-25 ⁇ g/m 2 ) to 120 ⁇ g/kg (360-3000 ⁇ g/m 2 ). In other embodiments, the dosing is from about 0.04-0.3 ⁇ g/kg (1 ⁇ g/m 2 ) to about 1-10 ⁇ g/kg (25 ⁇ g/m 2 ). In other embodiments, the dosing is from about 0.01 ⁇ g/m 2 to about 25 ⁇ g/m 2 . In other embodiments, the dosing is from about 0.0002-0.0004 ⁇ g/kg to about 0.05-1 ⁇ g/kg.
• the PKC activator is a PUFA administered at a dosage of about 0.001 to 100 mg/kg; 0.01 to about 50 mg/kg; about 0.1 to about 10 mg/kg.
• the PKC activator present in the compositions used in the methods of the present disclosure is a bryostatin or bryolog, and the bryostatin or bryolog is used in an amount from about 0.0001 to about 1000 milligrams.
• the bryostatin or bryolog is used in an amount from at least about 0.0001, 0.0005, 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, or about 1000.0 milligrams.
• compositions used in the methods of the present disclosure may be administered via any suitable route; for example, orally, intraperitoneally,
• compositions used in the methods of the present disclosure may be administered on a regimen of 1 to 4 times per day, and in some embodiments, the compositions are administered twice a week, once a week, once every two weeks, once every three weeks, once every four weeks, once every six weeks, once every eight weeks or even less frequently depending on the needs of the patient.
• compositions used in the methods of the present disclosure may be administered as part of a course of treatment lasting for about 1 to about 30 days; about 1 to about 90 days; about 1 to about 120 days; about 1 to about 180 days; about 1 to 365 days; one year; two years; three years; or for the patient's lifetime.
• the specific dose level and frequency of dosage for any particular host may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the nature of the disorder, the severity of the particular disorder, and the host undergoing therapy.
• Dulbecco's Modified Eagle Medium (DMEM), trypsin, L-glutamine, gentamicin, and NuPage gels and buffers were obtained from Invitrogen (Carlsbad, CA) while FBS was from Hyclone, Thermo Scientific (Rockford, IL).
• the monoclonal anti-vimentin (V9), conjugated anti-mouse-IgG and anti-rabbit- IgG antibodies were from Santa Cruz Biotechnologies, Inc. (Santa Cruz, CA).
• the anti-GAPDH antibody was from Millipore (Billerica, MA) and the anti-Rab9 polyclonal antibody has been described elsewhere [27].
• Filipin was from Polysciences, Inc. (Warrington, PA).
• Lumilight Plus substrate and FuGENETM 6 transfection reagent were both from Roche Diagnostics (Indianapolis, IN).
• the human wild-type fibroblast (GM05387), NPClo fibroblast (GM09341), and NPC1 fibroblast (GM03123) cell lines were obtained from Coriell Cell Repositories (Camden, NJ).
• the M12 Chinese hamster ovary (CHO) cell line and its wild-type parental line were obtained and cultured.
• Fibroblast cell lines were cultured in DMEM, and CHO cells were cultured in DMEM/F12 (50:50) medium, supplemented with 10% FBS, 2 mM L-glutamine, and 50 ⁇ g/ml gentamicin in a humidified incubator at 37°C with 5% C0 2 .
• the cDNA for PKC a was cloned into the bicistronic vector pIRES (Stratagene), which contains GFP for monitoring successful transfection.
• the cDNAs for PKC ⁇ , and PKC ⁇ (ATCC) were cloned into vector pYDual, which expresses a nuclear-targeted RFP (Ioannou, unpublished).
• a Rab9-YFP fusion construct (described in [5]) was used for Rab9 expression.
• Transient overexpression was achieved by transfecting cells at 70% confluency using the FuGENETM 6 reagent (Roche Diagnostics) according to the manufacturer's suggestions.
• Transfected cells were harvested with PBS containing 2 mM EDTA at 2 days post-transfection. Soluble and insoluble cell fractions were prepared as described previously [5]. Briefly, to obtain the soluble/cytoplasmic fraction, cells were incubated on ice for 30 min in cold "phospho" buffer [150 mM NaCl, 20 mM NaF, 100 ⁇ Na 3 V0 4 , 20 mM Hepes, pH 7.5), 1% (v/v) Igepal, 10% (v/v) glycerol, and 1 ⁇ 720 mg tissue of protease inhibitor cocktail] and then centrifuged for 20 min at 14,000 rpm at 4°C; the clear supernatant was frozen in aliquots at a concentration of 1 ⁇ g/ ⁇ l. The pellet
• filipin fluorescence For quantitation of filipin fluorescence, cells were seeded at 3 x 10 5 cells/well in 6-well dishes and allowed to settle overnight, after which the medium was replaced with medium containing 10% lipoprotein deficient serum (LPDS) for 4 days. Cells were incubated with oleic/linoleic acids for 48 hours, DCPLA/DHA for 24 hrs, or diazoxide for 72 hrs before fixing and staining with filipin as we have previously described. Images were acquired using the same exposure time for all samples. Fluorescence intensity was determined using the integrated intensity function of MetaVue software; at least 150 cells were quantitated for each sample and each experiment was repeated 3 times. For analysis of sphingo lipid transport, cells were incubated with oleic/linoleic acids, DCP-LA, or PMA for 48 hours before BODIPY-LacCer staining was performed as previously described [30].
• LPDS lipoprotein deficient serum
• NPCl cells with missense or null (NPClo) mutations contain decreased or virtually undetectable levels of soluble phosphorylated vimentin relative to WT cells, respectively [5]. Furthermore, the vimentin present in NPCl cells exists as large disorganized filaments (dephosphorylated state) near the plasma membrane. Thus, NPCl cells behave essentially as vimentin-null cells, which, similar to NPCl cells, are unable to esterify LDL-derived cholesterol [11]. In extending those studies, it was hypothesized that decreased vimentin phosphorylation was the result of protein kinase C (PKC) inhibition in NPCl cells.
• PPC protein kinase C
• NPC1 CHO (Ml 2) cells containing a deletion of the NPC1 locus [21] were transfected with PKC a or PKC ⁇ and the amount of LDL-derived free cholesterol transported from the E/L system to the ER for esterification by acyl-CoA: cholesterol acyltransferase (AC AT) [22] was measured.
• Esterification levels for Ml 2 cells were less than 10% of the esterification activity of the parental WT CHO cells ( Figure 3), which is consistent with a block in cholesterol transport out of the E/L system.
• Expression of PKC a or PKC ⁇ ameliorated the cholesterol transport block, increasing the level of M12 cell esterification by approximately 4- and 6.5-fold, respectively, over that of untransfected Ml 2 cells ( Figure 3, +PKCa, +PKCs).
• NPCl fibroblasts were treated with oleic or linoleic acid for 48 hours and the levels of soluble vimentin in cell lysates were analyzed. NPCl fibroblasts contain very little soluble vimentin ( Figure 5A and [5]). Treatment with either oleic or linoleic acid significantly increases the amount of soluble vimentin, with oleic acid being slightly more effective. These results suggest that exogenously added fatty acids can effect vimentin solubilization in NPCl cells, presumably by activating PKCs.
• DHA docosahexanoic acid
• DCP-LA a metabolite of linoleic acid
• vimentin may not be a direct substrate for certain PKCs, as has been shown with regards to PKC ⁇ - controlled phosphorylation of vimentin [10].
• PKC ⁇ mediated vimentin phosphorylation which was shown to be critical for proper integrin recycling through the cell.
• NPC genotype p.I1061T/p.I1061T
• Cells are plated in 6-well dishes and treated with the appropriate compound (dissolved in DMSO) at the indicated dose daily for 48 hrs. Control cells receive DMSO. After 48 hrs cells are transferred to cover slips with fresh compound and grown for another 24 hrs. Cover slips are collected and processed for microscopy.
• Verotoxin B Verotoxin B (VTB) : For VTB staining (glycosphingo lipid detection) cells are washed with PBS and fixed in formalin, 30 min, 4°C. Following a wash with 0.9% sodium chloride, 2X, 5 min at room temperature cells are permeabilized with digitonin 50 ⁇ g/well in 1.5ml PBS. Cells are washed with PBS, and alexa-labeled VTB is added at 0 ⁇ g/well in 1ml PBS. Cells are incubate 45min at RT on a shaker in the dark, washed with 0.9%) sodium chloride, 2X, 5 min at RT, and mounted for viewing.
• VTB staining glycosphingo lipid detection
• CTB Cholera toxin B
• NPC1 cells have a defective NPC1 protein and are characterized by the extreme accumulation of a number of lipids such as cholesterol, sphingo lipids and gangliosides in various endosomal vesicles ( Figure 2).
• lipids such as cholesterol, sphingo lipids and gangliosides in various endosomal vesicles ( Figure 2).
• filipin was used to detect the level of stored cholesterol (Assay protocol) whereas verotoxin B (VTB) allows the assessment of the levels of
• glycosphingolipids which are sometimes stored in endosomes distinct from those that contain cholesterol (Assay protocol).
• Assay protocol movement of gangliosides from the plasma membrane by using a different probe, cholera toxin can be monitored (Assay protocol).
• Bryostatin 1 also was effective in a kinetic assay that monitors the movement of lipids from the plasma membrane to the Golgi network through endosomes. At 10 mM bryostatin 1 was able to clear the endosome—trapped cholera toxin (CTB) from NPCl cells ( Figure 12).
• CTB cholera toxin
• bryostatin 1 was used at a range of 0.1 nM to 100 nM and evaluated both in cholesterol and sphingolipid assays (Figure 13). At 0.1 nM bryostatin has no effect in both assays. The effect becomes statistically significant at 1 nM and increases with increasing bryostatin 1 concentration.
• bryostatin 1 showed a positive therapeutic effect for human
• NPC1 disease cells at a concentration of 10-100 nM.
• Niemann-Pick C disease is a severe inherited lipidosis that leads to neurodegeneration and early childhood death.
• the biochemical and cellular events that lead to neurodegeneration are currently poorly understood.
• PKCs activation can restore the blocked lipid transport pathway and lead to a reduction of stored lipid material in the NPC endosomes/lysosomes.
• bryostatin 1 a natural product activator of PKCs
• mice A total of 30 C57B16 NPC1 mice, mixed sex, were used. These mice were separated into 5 groups of 5 mice each, Groups 1-5.
• Bryostatin 1 (purity >95%) from Aphios (Woburn, MA), 1 vial 2 mg, was solubilized in a 5% DMSO, 20% Solutol and 75% Saline solution and used as the study drug.
• the negative (vehicle) control is a 5% DMSO, 20% Solutol and 75% Saline solution.
• DCP-LA from Sigma- Aldrich: 5 mg oil/vial was used as an additional in vitro active compound.
• Bryostatin 1 (API) was stored at or below -20°C and formulated as needed. The formulated bryostatin 1 was stored at 2° to 8°C for less than 24 hour(s).
• the DCP-LA and the vehicle controls were stored at 2°-8°C.
• the stock solution of bryostatin 1 is 1 Omg/ml in DMSO, which is kept at -80°C in aliquots.
• the dosing formulation is made by diluting the stock first in DMSO, then adding solutol, and lastly saline— with more insoluble compounds, adding the drug stock to complete vehicle will cause the compound to come out of solution, so we make formulations stepwise.
• the dosing volume is always 100 ⁇ . Mice weigh approximately 20 g.
• the study agents are dosed intraperitoneally (IP) as shown in Table 3.
• IP intraperitoneally
• the mice are dosed twice weekly (Mon and Thu) starting at 30 days for up to 150 days.
• C57 NPC 1 mice have an average life span of ⁇ 110 days. By Day 70 mice reach an average weight of 18-22 grams. Untreated NPC1 mice develop ataxia and will begin to lose weight at -70 days (see Figure 17). Ataxia (or lack of voluntary muscle control) is a clinical feature of NPC 1 mice, which may be described as shaking.
• Treatment will be initiated at ⁇ 30 days of age, average NPC mouse weight of 10 g. If the drug is efficacious injections will continue past day 70-80. An extension of life of about 20-30% will mean that animals will need to be treated up to day 130-150.
• mice will be weighed and weights will be recorded prior to each injection. Mice may periodically be tested in a rotarod and time on rotarod will be recorded.
• Secondary outcomes include: (1) lipid accumulation in liver and spleen, and (2) cerebellar Purkinje cell survival and cholesterol storage (which are to be conducted only if the primary outcome is positive).
• mice in dose groups 30, 20 and 10 ⁇ g/kg lived past the age of 100 days.
• FR236924 induces a long-lasting facilitation of hippocampal neurotransmission by targeting nicotinic acetylcholine receptors.
• Diazoxide acts more as a PKC-epsilon activator, and indirectly activates the mitochondrial K(ATP) channel conferring cardioprotection against hypoxic injury.
• Type C Niemann-Pick disease a murine model of the lysosomal cholesterol lipidosis
• Niemann-Pick CI is a late endosome-resident protein that transiently associates with lysosomes and the trans-Golgi network.

Landscapes

• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• Emergency Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurosurgery (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Diabetes (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Priority Applications (9)

Applications Claiming Priority (4)

Related Child Applications (2)

Publications (1)

Family

ID=54321042

Family Applications (1)

Country Status (9)

Cited By (1)

Families Citing this family (1)

Citations (2)

Family Cites Families (7)

• 2015
  • 2015-04-14 MX MX2016013680A patent/MX2016013680A/es unknown
  • 2015-04-14 EP EP15780368.5A patent/EP3131543A4/en not_active Withdrawn
  • 2015-04-14 US US14/686,711 patent/US9724328B2/en not_active Expired - Fee Related
  • 2015-04-14 WO PCT/US2015/025821 patent/WO2015160851A1/en not_active Ceased
  • 2015-04-14 JP JP2017506619A patent/JP2017511387A/ja active Pending
  • 2015-04-14 US US15/304,838 patent/US20170172978A1/en not_active Abandoned
  • 2015-04-14 CN CN201580032762.2A patent/CN107072982A/zh active Pending
  • 2015-04-14 KR KR1020167032127A patent/KR20170031653A/ko not_active Withdrawn
  • 2015-04-14 CA CA2946115A patent/CA2946115A1/en not_active Abandoned
• 2016
  • 2016-10-25 IL IL248494A patent/IL248494A0/en unknown
• 2019
  • 2019-01-15 US US16/247,880 patent/US20190201377A1/en not_active Abandoned

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events